Skip to main content
Premium Trial:

Request an Annual Quote

Bristol-Myers Squibb Renews License for Ingenuity Systems Software

NEW YORK (GenomeWeb News) – Bristol-Myers Squibb has renewed its license for Ingenuity Systems’ pathway analysis software for use in genomics and proteomics research aimed at advancing its drug discovery programs, Ingenuity said today.
 
Under the agreement, Bristol-Myers Squibb gains enterprise-wide access to the Ingenuity Pathways Analysis software for modeling, visualization, and interpretation of genomics and proteomics data. BMS has been an Ingenuity customer since 2004.
 
The IPA software supports data from a variety of experimental platforms and at “all stages of the drug discovery and development process,” including biomarker discovery, target identification and validation, pharmacogenomics, metabolomics, and molecular toxicology, Ingenuity said.
 
Financial terms of the agreement were not released.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.